All the news from Novigenix
Follow all the news from Novigenix
Breakthrough study reveals blood transcriptomic alternations for early detection of colorectal cancer
Lausanne, Switzerland, November 25, 2024 – Novigenix, a leader in AI-driven healthcare solutions, has published a new study marking a significant milestone in advancing early colorectal cancer (CRC) detection through innovative immune system profiling. The groundbreaking research, “Human blood cell transcriptomics unveils dynamic systemic immune modulation along colorectal cancer progression,” [link] has been published in the Journal for Immunotherapy of Cancer. Dr. Pedro Romero, Chief Medical
Understanding Tumor Immunology: How AI-powered blood RNA analysis could unlock immunotherapy prognoses
By Pedro Romero, Chief Medical & Scientific Officer of Novigenix - Identifying markers in body fluids via liquid biopsy holds great promise for detecting diseases (such as cancer) at early stages, following disease progression and population heterogeneity, and, importantly, predicting a response to therapy with minimal patient inconvenience. Liquid biopsy relies on easy access to a multitude of molecular
Prostate cancer breakthrough: Novigenix-led project receives €1.75M grant to improve patient outcomes using liquid biopsy technology
Lausanne, Switzerland, September 24, 2024 – Groundbreaking funding promises to revolutionize care for patients with advanced prostate cancer by addressing treatment resistance through innovative liquid biopsy technology. Novigenix, a leader in AI-driven healthcare solutions, has today announced the approval of a Eurostars grant for the MYeloid SIGNATUREs (MY-SIGNATURE) project. This prestigious grant, totaling a consortium budget of €1.75 million,
Novigenix unveils multimodal liquid biopsy approach at ESMO 2024, advancing precision medicine with AI-powered immune profiling
Lausanne, Switzerland, September 12, 2024 – Novigenix, an innovator in precision medicine and liquid biopsy technologies, will showcase its multimodal approach at the European Society for Medical Oncology (ESMO) 2024 conference. This is poised to revolutionize the landscape of oncology treatment and drug development. The new approach combines advanced immune profiling with cell-free DNA (cfDNA) analysis, providing a comprehensive view of the
Novigenix receives ISO 13485 Certification from BSI
Geneva, September 11, 2024 - Novigenix, a leader in AI-driven healthcare solutions, successfully achieved ISO 13485:2016 certification, passing the Stage II audit with zero non-conformities. This milestone underscores Novigenix's unwavering commitment to the highest standards of quality in providing solutions for the biopharma industry. ISO 13485:2016 is an internationally recognized standard for quality management systems in the medical device industry.
Novigenix honored as Best 2024 Technology Innovation in oncology by MATWIN Board
Lausanne, May 29, 2024 – Novigenix, a leader in AI-driven healthcare solutions, has been awarded the prestigious recognition of 'Best 2024 Technology Innovation' in oncology by the MATWIN Board, the premier European convention dedicated to innovation in cancer treatment. This recognition highlights Novigenix's groundbreaking contributions to personalized cancer care and its commitment to advancing oncology through cutting-edge technology. Brian
Revolutionizing Colorectal Cancer Screening with Novigenix Innovations
Recent research in the New England Journal of Medicine highlights significant advances in colorectal cancer (CRC) screening. Novigenix leads this innovation with our unique approach that combines liquid biopsy, AI, and RNA analysis, promising a transformative impact on early cancer detection. Colorectal cancer is a major global health concern, projected to rise by 63% by 2040. Despite current screening
Novigenix and IMMUcan forge a transformative partnership in AI-driven immunotherapy advancements
04.04.2024, Geneva - In a significant step forward for personalized cancer care, Novigenix, a pioneer in AI healthcare solutions, has been selected as a key partner by the IMMUcan consortium for the development of RNA sequencing biomarkers and to advance the understanding of the immune system's response to checkpoint inhibitors in cancer patients. IMMUcan consortium aims to advance cancer research
Revolutionizing drug development: Novigenix unveils AI-powered RNA analysis for immune response profiling
Geneva, January 16, 2024 - With cancer projected to escalate to 29 million cases by 2040[1], Novigenix, a pioneer in AI healthcare solutions, is rewriting the rules of cancer care. Their newest innovation, LITOSeek™, is primed to reshape drug development, offering a transformative leap forward. Personalized Cancer Treatment: Breaking Barriers Every cancer is as unique as the person it
Novigenix appoints Dr. Pedro Romero as Chief Medical & Scientific Officer
LAUSANNE, SWITZERLAND – Novigenix, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, recently announced the appointment of Dr Pedro Romero, MD, PhD as its Chief Medical & Scientific Officer. Dr. Romero has previously served as Director of Medical & Scientific Affairs and on the Medical Advisory Board of Novigenix. In his new role as Chief
Novigenix presenting at BioTechX Europe 2023, “AI- Powered RNA Analytics to Drive Innovation in Cancer Therapy through Liquid Biopsy”, Oct 5th, 2:50 PM
Novigenix is a pioneering, precision medicine biotech, focusing on AI-RNA analysis to improve treatment outcomes for cancer patients. Our immuno- transcriptomic solutions make earlier detection of disease possible, capture the immune profile of the patient in order to predict likely response to treatment, and enable novel drug development. The Novigenix platform is optimized for whole-blood RNA biomarkers, and mapping
Novigenix Reports Interim European Validation Data on its New NGS-based Whole Blood RNA Signature for detection of Advanced Colorectal Adenomas
LAUSANNE, SWITZERLAND – Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced presentation of its interim European validation data for its whole blood RNA signature for early detection of pre-cancerous colorectal cancer legions (Advanced Colorectal Adenomas). The data is presented at the European Society for Medical Oncology (ESMO) GI
Novigenix Appoints Dr. Pedro Romero as Director of Medical & Scientific Affairs
LAUSANNE, SWITZERLAND – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced appointment of Dr. Pedro Romero as Director of Medical & Scientific Affairs. Dr. Romero has previously served on the Medical Advisory Board of Novigenix and brings over three decades of experience in immunology and immune oncology expertise to the team.
Novigenix announces first closing of its $20M Series B financing round
Expansion of Biopharma precision solutions in the field of Immuno-Oncology LAUSANNE, SWITZERLAND - November 15, 2022 – Novigenix SA, a leading data-driven precision medicine biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced successful first closing of its $20 million Series B financing round with participation from existing and new investors. Novigenix‘s Liquid Immuno-Transcriptomic (LITOseek) platform provides
Novigenix announces discovery of liquid biopsy immunotherapy response biomarkers in metastatic Melanoma
New LITOseek biomarkers presented at ESMO have identified upregulation of ribosomal biogenesis and TCR signaling with downregulation of interferon gene clusters in responsive patients LAUSANNE, SWITZERLAND - September 9th, 2022 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions today announced discovery of new Immuno-Transcriptomic signatures for prediction of response to immunotherapy and patient
Novigenix and Philips Sign Technology License Agreement for Prostate Cancer Precision Oncology Products
New precision solutions may be accessible on Philips IntelliSpace Precision Medicine Platform LAUSANNE, SWITZERLAND - March 8, 2022 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced a Technology License Agreement with Royal Philips (‘Philips’) for development of new tissue biopsy Prostate cancer (PCa) Immuno-Transcriptomic tests to improve prostate cancer patient outcomes.
Novigenix and Radboud University Medical Center Discover the First Blood-Based ImmunoTranscriptomic biomarkers for Response to Anti-PD-1 therapy
Publication in Cancers Journal Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 LAUSANNE, SWITZERLAND - September 23rd, 2021 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced release of the article: “Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker
Novigenix Announces Election of Dr. Miro Venturi to its Board of Directors
Company expands precision medicine solutions for drug development and clinical utility programs. LAUSANNE, SWITZERLAND - August 31, 2021 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced election of Dr. Miro Venturi to its Board of Directors. Dr. Venturi is currently Group CEO of Sintetica SA, a Swiss based multinational pharmaceutical
Novigenix highlighted in online Focus article
Schweizer Firma erhält Felix Burda Award für Bluttest, der Darmkrebs erkennt Ein Biotech-Unternehmen hat einen Bluttest entwickelt, der Darmkrebs und dessen Vorstufen mit hoher Wahrscheinlichkeit erkennt. Die Basis dafür bilden Biomarker im Blut. Für diesen Fortschritt in der Darmkrebs-Vorsorge erhalten sie den Felix Burda Award 2021. Im zweiten Teil der virtuellen Preisverleihung geht der Felix Burda Award 2021 in
Novigenix Wins the 2021 Felix Burda Award in Medicine & Science
Novigenix Wins the 2021 Felix Burda Award in Medicine & Science • Category ‘Innovation in Immuno-Transcriptomics for Early Detection of Colorectal Cancer’ • Award recognizes excellence in innovation and impact in early detection of cancer LAUSANNE, SWITZERLAND - July 22, 2021 – Novigenix SA, a leading Swiss biotech that develops and commercializes Immuno-Transcriptomic precision oncology solutions, today announced that
Novigenix-Led Consortium Secures Eurostars Funding to Develop Predictive Immune Checkpoint Inhibitor Test
Total amount up to €1 million awarded to consortium of leading cancer centers and innovative healthcare companies LAUSANNE, SWITZERLAND – 07:00 CET, December 22, 2020 Novigenix SA Switzerland, a pioneer in Immuno-Transcriptomics for precision medicine today announced that a consortium, including PamGene International BV and Radboud University (The Netherlands), has been awarded a grant up to €1 million to develop a blood based
Novigenix presents new Immuno-Transcriptomic data for prediction of response to immunotherapy in metastatic urothelial cancer patients
Newly discovered blood signature presented at ESMO 2020 LAUSANNE, SWITZERLAND – 07:00 CET, September 17th, 2020 – Novigenix SA, a pioneer in Immuno-Transcriptomics for precision oncology, today announced a new Immuno-Transcriptomic signature for predicting response to immunotherapy in metastatic urothelial cancer patients. The data are presented at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress (17-21september 2020 at
Novigenix-Led Consortium Secures Eurostars Funding to Develop Multi-Omics Test for Colon Cancer Detection and Monitoring
Total amount up to €1 million awarded to consortium of leading cancer centers and innovative healthcare companies LAUSANNE, SWITZERLAND - 07:00 CET, January 21, 2020 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced that a consortium, including Maastricht University (The Netherlands), Biolizard and the KU Leuven
Novigenix Develops New NGS-based Immune Cell Type Specific RNA Signatures for Early Colon Cancer Detection
Immune cell type specific profiles correlate with traditional blood cell count method LAUSANNE, SWITZERLAND - 07:00 CET, December 11, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced the development of a new immune cell type specific Immuno-Transcriptomic signature for the detection of colorectal cancer (CRC) in
Novigenix and RadioMedix to Develop Neuroendocrine Cancer Precision Diagnostic Test
Test to measure response to radiopharmaceutical therapy LAUSANNE, SWITZERLAND - 07:00 CET, October 14, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced a collaboration agreement with RadioMedix Inc., a radiopharmaceutical company, to develop a precision diagnostic test based on Novigenix’s technology. The test will measure the
Novigenix Receives Reimbursement Coverage for Colox® in Switzerland
First liquid biopsy test reimbursed in Switzerland for colon cancer screening through private outpatient supplementary insurance product offered by Helsana LAUSANNE, SWITZERLAND - 07:00 CET, October 9, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine. today announced that Helsana, the leading health insurance provider in Switzerland, has started
Novigenix’s New Early Colon Cancer Detection Blood Test Demonstrates Positive Results
Data on test’s newly discovered blood signature presented at ESMO 2019 LAUSANNE, SWITZERLAND - 07:00 CET, September 30, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced promising data from a study of a new Immuno-Transcriptomic signature for early detection of colorectal cancer (CRC) in blood. The
Novigenix to Present Data on New Molecular Signature for Early Detection of Colon Cancer at ESMO 2019
Company Launches New Website to Enhance New Strategy Company to present at the Convergence of Oncology meeting in Lausanne LAUSANNE, SWITZERLAND - 07:00 CET, September 10, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes solutions for early cancer detection and precision medicine, today announced the discovery of a new molecular signature in blood that can be
Interview Jan Groen: Colorectal Cancer Blood Test Driven by Immuno-transcriptomics
Source: TN Michele Wilson PhD Science Writer Immuno-transcriptomics is a field of study focused on analyzing gene expression modifications (mRNA signatures) induced by the immune response to various triggers, such as the onset of cancer. Through deep neural network and machine learning, Novigenix are generating mathematical models based on these mRNA signature analyses to predict the onset and progression
Novigenix Strengthens Board with Appointment of Francois Martelet, M.D. Non-Executive Director
LAUSANNE, SWITZERLAND - 07:00 CET, June 18, 2019 - Novigenix SA, a leading Immuno-Transcriptomics company that develops and commercializes products for early cancer detection and precision medicine today announced the appointment of Francois Martelet, M.D. to its Board of Directors as a non-executive director. Dr. Martelet has over 25 years’ experience at both corporate and operational level in pharmaceutical and biotech
Novigenix Developing NGS Version of Early Colorectal Cancer Detection Test
NEW YORK (GenomeWeb) – With a new CEO at its helm, Swiss molecular diagnostic firm Novigenix is developing a new version of Colox, its mRNA-based assay for early colorectal cancer detection that applies next-generation sequencing instead of RT-PCR. The firm began a study earlier this year to validate the assay, which measures cancer-specific transcriptomic signatures in circulating immune cells,
Novigenix Appoints Dr. Jan Groen as CEO to Lead Expansion to Multi-Product Cancer Diagnostic Platform Company
ImmunoTranscriptomic platform combines identification of immune cell mRNA signatures with AI for early cancer detection LAUSANNE, SWITZERLAND - 07:00 CET, May 13, 2019 - Novigenix SA, a leading ImmunoTranscriptomics company that develops and commercializes products for early cancer detection and precision medicine today announced the appointment of Dr. Jan Groen to the position of Chief Executive Officer and member of
Mars Bleu, a campaign to raise awareness about colorectal cancer screening
Mars Bleu, a campaign to raise awareness about colorectal cancer screening You may have heard about Pink October, a month dedicated to breast cancer awareness and screening. If you didn’t know it yet, there is also the national colorectal cancer awareness month; it’s March and it’s called Mars Bleu (Blue March). Colorectal cancer is the second most deadly cancer
Geneva pharmacies engage in the fight against colorectal cancer
Geneva pharmacies engage in the fight against colorectal cancer The campaign “Mars Bleu” (Blue March) is an opportunity to develop a new network and to make screening even more accessible. In March, 20 Geneva’s drug stores partner with Novigenix for the fight against colorectal cancer by promoting different non-invasive screening solutions including the molecular blood test Colox and fecal
Colox® an innovation made in Switzerland
Colon cancer kills 5 people every day in Switzerland. "An unacceptable reality", said Brian Hashemi, chairman of Novigenix, a biotech start-up at the heart of the Biopôle in Lausanne. Unacceptable because with early detection, colorectal cancer can be cured. Now the second most deadly form of cancer, the eradication of colorectal cancer represents both a global health challenge and
Find relevant information about colorectal cancer
Know the symptoms, but don’t wait to get screened
Colorectal cancer progresses slowly and doesn’t show signs or symptoms until an advanced stage1. Thus, people who get cancer are diagnosed late whereas an early detection increases the chances of survival. Even if we don't have to wait for the first symptoms to get screened, it is important to recognize the signs that may be associated to colorectal cancer. In the article from Colorectal Cancer
Can Colorectal Cancer Be Prevented?
Even if there is no sure way to prevent colorectal cancer, there are things you can do that might help lower your risk. Screening is one of those factors you can control and which help you to reduce the risk to develop a colorectal cancer. The earlier a colorectal cancer is detected, the easier it is treated. Screening is very
Colorectal cancer screening should be self-evident
PREVENTION : Colorectal cancer screening is voluntary but the physicians strongly recommend it Prof. Dr. med. Christoph Beglinger - Specialist of Gastroenterology Colorectal Cancer - Screening : Now, there are three options for the prevention. Switzerland lags behind regarding colorectal cancer screening, according to international comparison. Only 30% of men and women over the age of 50 get screened. In fact,